BACKGROUND: Episodic memory impairment is the core feature of typical Alzheimer's disease. OBJECTIVE: To evaluate the performance of two commonly used verbal memory tests to detect mild cognitive impairment due to Alzheimer's disease (MCI-AD) and to predict progression to Alzheimer's disease dementia (AD-d). METHODS: Prospective study of MCI patients in a tertiary memory disorder unit. Patients underwent an extensive neuropsychological battery including two tests of declarative verbal memory: The Free and Cued Selective Reminding Test (FCSRT) and the word list learning task from the Consortium to Establish a Registry for Alzheimer's disease (CERAD-WL). Cerebrospinal fluid (CSF) was obtained from all patients and MCI-AD was defined by means of the t-Tau/Aβ1-42 ratio. Logistic regression analyses tested whether the combination of FCSRT and CERAD-WL measures significantly improved the prediction of MCI-AD. Progression to AD-d was analyzed in a Cox regression model. RESULTS: A total of 202 MCI patients with a mean follow-up of 34.2±24.2 months were included and 98 (48.5%) met the criteria for MCI-AD. The combination of FCSRT and CERAD-WL measures improved MCI-AD classification accuracy based on CSF biomarkers. Both tests yielded similar global predictive values (59.9-65.3% and 59.4-62.8% for FCSRT and CERAD-WL, respectively). MCI-AD patients with deficits in both FCSRT and CERAD-WL had a faster progression to AD-d than patients with deficits in only one test. CONCLUSIONS: The combination of FCSRT and CERAD-WL improves the classification of MCI-AD and defines different prognostic profiles. These findings have important implications for clinical practice and the design of clinical trials.
BACKGROUND:Episodic memory impairment is the core feature of typical Alzheimer's disease. OBJECTIVE: To evaluate the performance of two commonly used verbal memory tests to detect mild cognitive impairment due to Alzheimer's disease (MCI-AD) and to predict progression to Alzheimer's disease dementia (AD-d). METHODS: Prospective study of MCI patients in a tertiary memory disorder unit. Patients underwent an extensive neuropsychological battery including two tests of declarative verbal memory: The Free and Cued Selective Reminding Test (FCSRT) and the word list learning task from the Consortium to Establish a Registry for Alzheimer's disease (CERAD-WL). Cerebrospinal fluid (CSF) was obtained from all patients and MCI-AD was defined by means of the t-Tau/Aβ1-42 ratio. Logistic regression analyses tested whether the combination of FCSRT and CERAD-WL measures significantly improved the prediction of MCI-AD. Progression to AD-d was analyzed in a Cox regression model. RESULTS: A total of 202 MCI patients with a mean follow-up of 34.2±24.2 months were included and 98 (48.5%) met the criteria for MCI-AD. The combination of FCSRT and CERAD-WL measures improved MCI-AD classification accuracy based on CSF biomarkers. Both tests yielded similar global predictive values (59.9-65.3% and 59.4-62.8% for FCSRT and CERAD-WL, respectively). MCI-ADpatients with deficits in both FCSRT and CERAD-WL had a faster progression to AD-d than patients with deficits in only one test. CONCLUSIONS: The combination of FCSRT and CERAD-WL improves the classification of MCI-AD and defines different prognostic profiles. These findings have important implications for clinical practice and the design of clinical trials.
Authors: Alberto Lleó; Raúl Núñez-Llaves; Daniel Alcolea; Cristina Chiva; Daniel Balateu-Paños; Martí Colom-Cadena; Gemma Gomez-Giro; Laia Muñoz; Marta Querol-Vilaseca; Jordi Pegueroles; Lorena Rami; Albert Lladó; José L Molinuevo; Mikel Tainta; Jordi Clarimón; Tara Spires-Jones; Rafael Blesa; Juan Fortea; Pablo Martínez-Lage; Raquel Sánchez-Valle; Eduard Sabidó; Àlex Bayés; Olivia Belbin Journal: Mol Cell Proteomics Date: 2019-01-03 Impact factor: 5.911
Authors: Isabelle Bos; Stephanie J B Vos; Willemijn J Jansen; Rik Vandenberghe; Silvy Gabel; Ainara Estanga; Mirian Ecay-Torres; Jori Tomassen; Anouk den Braber; Alberto Lleó; Isabel Sala; Anders Wallin; Petronella Kettunen; José L Molinuevo; Lorena Rami; Gaël Chetelat; Vincent de la Sayette; Magda Tsolaki; Yvonne Freund-Levi; Peter Johannsen; Gerald P Novak; Inez Ramakers; Frans R Verhey; Pieter Jelle Visser Journal: Front Aging Neurosci Date: 2018-06-25 Impact factor: 5.750
Authors: Estrella Morenas-Rodríguez; Daniel Alcolea; Marc Suárez-Calvet; Laia Muñoz-Llahuna; Eduard Vilaplana; Isabel Sala; Andrea Subirana; Marta Querol-Vilaseca; María Carmona-Iragui; Ignacio Illán-Gala; Roser Ribosa-Nogué; Rafael Blesa; Christian Haass; Juan Fortea; Alberto Lleó Journal: Sci Rep Date: 2019-05-24 Impact factor: 4.379
Authors: C Delaby; D Alcolea; M Carmona-Iragui; I Illán-Gala; E Morenas-Rodríguez; I Barroeta; M Altuna; T Estellés; M Santos-Santos; J Turon-Sans; L Muñoz; R Ribosa-Nogué; I Sala-Matavera; B Sánchez-Saudinos; A Subirana; L Videla; B Benejam; S Sirisi; S Lehmann; O Belbin; J Clarimon; R Blesa; J Pagonabarraga; R Rojas-Garcia; J Fortea; A Lleó Journal: Sci Rep Date: 2020-06-08 Impact factor: 4.379
Authors: Ignacio Illán-Gala; Jordi Pegueroles; Victor Montal; Daniel Alcolea; Eduard Vilaplana; Alexandre Bejanin; Sergi Borrego-Écija; Frederic Sampedro; Andrea Subirana; María-Belén Sánchez-Saudinós; Ricard Rojas-García; Hugo Vanderstichele; Rafael Blesa; Jordi Clarimón; Anna Antonell; Albert Lladó; Raquel Sánchez-Valle; Juan Fortea; Alberto Lleó Journal: Ann Clin Transl Neurol Date: 2019-12-02 Impact factor: 4.511
Authors: Constance Delaby; Teresa Estellés; Nuole Zhu; Javier Arranz; Isabel Barroeta; María Carmona-Iragui; Ignacio Illán-Gala; Miguel Ángel Santos-Santos; Miren Altuna; Isabel Sala; M Belén Sánchez-Saudinós; Laura Videla; Sílvia Valldeneu; Andrea Subirana; Mireia Tondo; Francisco Blanco-Vaca; Sylvain Lehmann; Olivia Belbin; Rafael Blesa; Juan Fortea; Alberto Lleó; Daniel Alcolea Journal: Alzheimers Res Ther Date: 2022-02-01 Impact factor: 6.982